Company Overview and News
SINGAPORE/HANOI (June 22): Bank for Foreign Trade of Vietnam JSC, the nation’s biggest listed lender by market value, appointed Credit Suisse Group AG to advise on finding a new insurance distribution partner, people with knowledge of the matter said.
MFC.PR.B MFC.PR.F DGLD MFC.PR.C BNPQY CS UGLD D05 DBSDF DSLV DBSDY VIIX CSSLF VIIZ BNPQF BNPZY CSGKF MFC 0945 MFC.PR.I MFC.PR.J ZIV USLV MFC MFC.PR.H TVIX 8750 MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L XIV
TOKYO, May 30 (Reuters) - Japan’s Nikkei share average tumbled to six-week lows on Wednesday after political turmoil in Italy sparked concerns over the stability of the euro zone, hitting financial and exporter shares in particular.
7261 HACBY MKTAY MZDAY HRSMF 8306 MZDAF HACBF MUFG 8359 8301 8379 8750 MBFJF 8630 MTU
Traders said they expected the Bank of Japan to buy exchange-traded funds to support the market amid the morning weakness. - Reuters
7261 MZDAY TM SMFG TYT TOYOF SMFNF 532843 FORTIS 6501 8316 8306 MZDAF 7203 MUFG 8750 HTHIY MBFJF 8630 MTU
TOKYO, May 30 (Reuters) - Japan’s Nikkei share average tumbled to six-week lows on Wednesday morning after political turmoil in Italy sparked concerns about the stability of the euro zone, hurting most sectors on the board.
7261 MZDAY TM SMFG TYT TOYOF SMFNF 6501 8316 8306 MZDAF 7203 MUFG 8750 HTHIY MBFJF 8630 MTU
The following slide deck was published by Dai-ichi Life Holdings, Inc. ADR in conjunction with their 2018 Q4 earnings call.
During the week, Union Bank of India said Japan's Dai-ichi Life Holdings acquired 39.62 percent stake in Union Asset Management through investment in compulsorily convertible preference shares.
On one hand, we are seeing exits of foreign partners from the domestic mutual fund industry while on the other hand, a set of global players still find the Indian mutual fund industry attractive.
UBNC MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA 8750
TOKYO, May 18 (Reuters) - Japan’s Nikkei share average rose to a 3-1/2-month high on Friday and scored its eighth straight weekly gain after a weaker yen lifted exporters, while financial stocks extended their rally as U.S. bond yields remained high.
Japan's Nikkei share average rose to a 3-1/2-month high on Friday morning after a weaker yen lifted exporters, while financial stocks extended their rally as US bond yields remained high.
TOKYO, May 18 (Reuters) - Japan’s Nikkei share average rose to a 3-1/2-month high on Friday morning after a weaker yen lifted exporters, while financial stocks extended their rally as U.S. bond yields remained high.
Asian markets were muted in early trading Friday, as investors appeared to be readjusting their expectations about trade negotiations between the U.S. and China.
BC94 SMSN 8750 SMSD
TOKYO, May 17 (Reuters) - Japan’s Nikkei share average followed U.S. stocks higher on Thursday morning after Wall Street gained overnight, with financial stocks rallying on an increase in U.S. bond yields.
KYO ADTTF 8316 8306 MUFG SMFG 8750 SMFNF MBFJF ATEYY MTU
Stocks nose-dived on the Tokyo Stock Exchange Friday due to intensifying concerns over a trade war between the United States and China, with the benchmark 225-issue Nikkei average finishing with a loss of nearly 1,000 points.
TM SMFG YASKY SFTBF SMFNF TOELY 6506 8306 8766 KUBTY TKOMY TOELF MBFJF SFTBY YASKF TKOMF TYT TOYOF 8316 7203 9984 8750 5020 8035 MTU
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...